Muscle and liver lactate metabolism in HAART-treated and naive HIV-infected patients: The MITOVIR study

Antiviral Therapy

Volumn 10, Issue 4, 2005, Pages 543-550

  Ghosn, Jade ^a,b   Guiguet, Marguerite ^b   Jardel, Claude ^a,b   Benyaou, Rabah ^b   Zeller, Valérie ^a   Simon, Anne ^a   Valantin, Marc Antoine ^a,b   Amellal, Bahia ^a   Assoumo, Lambert ^b   Hogrel, Jean Yves ^b   Costagliola, Dominique ^b   Katlama, Christine ^a,b   Lombès, Anne ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LACTIC ACID; LAMIVUDINE; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CELL LEVEL; CONTROLLED STUDY; EXERCISE TEST; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; MUSCLE METABOLISM; MUSCLE MITOCHONDRION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LACTIC ACID; LIVER; MALE; MIDDLE AGED; MUSCLE, SKELETAL;

EID: 23044499234     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ & Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 1998; 338:853-860.
2. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA & Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-1744.
3. Brinkman K, Smeitink JA, Romijn JA & Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
4. Birkus G, Hitchcock MJ & Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrobial Agents & Chemotherapy 2002; 46:716-723.
5. McComsey G, Tan DJ, Lederman M, Wilson E & Wong LJ. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 2002; 16:513-518.
6. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ & Mallal SA. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001;15:717-723.
7. Falco V, Rodriguez D, Ribera E, Martinez E, Miro JM, Domingo P, Diazaraque R, Arribas JR, Gonzalez-Garcia JJ, Montero F, Sanchez L & Pahissa A. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clinical Infectious Diseases 2002; 34:838-846.
8. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D & Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16:1341-1349.
9. Leverve X, Mustafa I & Perronet F. Pivotal role of lactate in aerobic metabolism. In Yearbook of Intensive Care and Emergency Medicine, 1998; pp. 588-596. Edited by Vincent J Berlin: Springer Verlag.
10. Madias NE. Lactic acidosis. Kidney International 1986; 29:752-774.
11. Stacpoole PW. Lactic acidosis and other mitochondrial disorders. Metabolism 1997; 46:306-321.
12. Chattha G, Arieff AI, Cummings C & Tierney LM Jr. Lactic acidosis complicating the acquired immunodeficiency syndrome. Annals of Internal Medicine 1993; 118:37-39.
13. Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, Schaeffer A & Zafrani ES. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. Journal of Hepatology 1999; 30:156-160.
14. Hogrel JY, Laforet P, Ben Yaou R, Chevrot M, Eymard B & Lombes A. A non-ischemic forearm exercise test for the screening of patients with exercise intolerance. Neurology 2001; 56:1733-1738.
15. Chiolero R, Tappy L, Gillet M, Revelly JP, Roth H, Cayeux C, Schneiter P & Leverve X. Effect of major hepatectomy on glucose and lactate metabolism. Annals of Surgery 1999; 229:505-513.
16. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G & Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. Journal of Clinical Endocrinology & Metabolism 2000; 85:2402-2410.
17. Bieche I, Olivi M, Champeme MH, Vidaud D, Lidereau R & Vidaud M. Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. International Journal of Cancer 1998; 78:661-666.
18. Gourlain K, Amellal B, Ait Arkoub Z, Dupin N, Katlama C & Calvez V. Quantitative analysis of human mitochondrial DNA using a real-time PCR assay. HIV Medicine 2003; 4:287-292.
19. DiMauro S & Schon EA. Mitochondrial respiratory-chain diseases. New England Journal of Medicine 2003; 348:2656-2668.
20. Roge BT, Calbet JA, Moller K, Ullum H, Hendel HW, Gerstoft J & Pedersen BK. Skeletal muscle mitochondrial function and exercise capacity in HIV-infected patients with lipodystrophy and elevated P-lactate levels. AIDS 2002; 16:973-982.
21. Bauer AM, Sternfeld T, Horster S, Schunk M, Goebel FD & Bogner JR. Kinetics of lactate metabolism after submaximal ergometric exercise in HIV-infected patients. HIV Medicine 2004; 5:371-376.
22. Chapplain JM, Beillot J, Begue JM, Souala F, Bouvier C, Arvieux C, Tattevin P, Dupont M, Chapon F, Duvauferrier R, Hespel JP, Rochcongar P & Michelet C. Mitochondrial abnormalities in HIV-infected lipoatrophic patients treated with antiretroviral agents. Journal of Acquired Immune Deficiency Syndromes 2004; 37:1477-1488.
23. Cade WT, Fantry LE, Nabar SR & Keyser RE. Decreased peak arteriovenous oxygen difference during treadmill exercise testing in individuals infected with the human immunodeficiency virus. Archive of Physical Medicine & Rehabilitation 2003; 84:1595-1603.
24. Leclercq P, Roth H, Bosseray A & Leverve X. Investigating lactate metabolism to estimate mitochondrial status. Antiviral Therapy 2001; 6(Suppl4):16.
25. Van Huyen JP, Landau A, Piketty C, Belair MF, Batisse D, Gonzalez-Canali G, Weiss L, Jian R, Kazatchkine MD & Bruneval P. Toxic effects of nucleoside reverse transcriptase inhibitors on the liver. Value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy. American Journal of Clinical Pathology 2003; 119:546-555.
26. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave JP, Bernasconi E, Egger M, Opravil M, Rickenbach M, Francioli P & Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clinical Infectious Diseases 2001; 33:1931-1937.
27. Bonnet F, Bonarek M, Abridj A, Mercie P, Dupon M, Gemain MC, Malvy D, Bernard N, Pellegrin JL, Morlat P & Beylot J. Severe lactic acidosis in HIV-infected patients treated with nucleosidic reverse transcriptase analogs: a report of 9 cases. Revue de Medecine Interne 2003; 24:11-16.
28. Brinkman K. Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clinical Infectious Diseases 2000; 1:167-169.
29. McComsey GA, Paulsen DM, Lonergan JT, Hessenthaler SM, Hoppel CL, Williams VC, Fisher RL, Cherry CL, White-Owen C, Thompson KA, Ross ST, Hernandez JE & Ross LL. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19:15-23.
30. Cossarizza A, Riva A, Pinti M, Ammannato S, Fedeli P, Mussini C, Esposito R & Galli M. Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antiviral Therapy 2003; 8:315-321.
31. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV & Montaner JS. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. New England Journal of Medicine 2002; 346:811-820.
32. Walker UA, Bauerle J, Laguno M, Murillas J, Mauss S, Schmutz G, Setzer B, Miquel R, Gatell JM & Mallolas J. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39:311-317.
33. Zaera MG, Miro O, Pedrol E, Soler A, Picon M, Cardellach F, Casademont J & Nunes V. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS 2001; 15:1643-1651.
34. Lonergan JT, Barber RE & Mathews WC. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS 2003; 17:2495-2499.
35. Nerurkar PV, Pearson L, Frank JE, Yanagihara R & Nerurkar VR. Highly active antiretroviral therapy (HAART)-associated lactic acidosis: in vitro effects of combination of nucleoside analogues and protease inhibitors on mitochondrial function and lactic acid production. Cellular & Molecular Biology 2003; 49:1205-1211.
36. Carr A, Samaras K, Chisholm DJ & Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881-1883.